Neoadjuvant chemotherapy for treatment patients with rectal cancer with adverse prognostic factors: A review
- 作者: Nevolskikh A.1,2, Avdeenko V.1,2, Belokhvostova A.1, Mikhaleva Y.1, Pochuev T.1, Zibirov R.1,2, Ivanov S.1,2,3, Kaprin A.4,3
-
隶属关系:
- Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre
- Obninsk Institute for Nuclear Power Engineering
- People’s Friendship University of Russia (RUDN University)
- National Medical Research Radiological Centre
- 期: 卷 24, 编号 3 (2022)
- 页面: 389-398
- 栏目: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/109317
- DOI: https://doi.org/10.26442/18151434.2022.3.201806
- ID: 109317
如何引用文章
全文:
详细
Rectal cancer (RC) is one of the leading tumor location in the structure of the incidence of malignant neoplasms in the Russian Federation and the world. And the standard approach to the treatment of patients with locally advanced forms of RC is preoperative chemo-radiotherapy (CRT) with delayed surgery. The use of such sort of approach in the recent decades has led to the reduction of the frequency of local recurrence up to 10% and even less. However, approximately a third of patients die of distant metastases. In this regard, one of the main tasks in the treatment of patients with locally advanced forms of RC with adverse prognostic factors is the prevention of distant metastasis formation. Early initiation of the systemic therapy before surgery is aimed at solving this issue. Conducting neoadjuvant chemotherapy (NCT) instead of CRT in RC treatment allows to avoid radiation reactions and injuries, occurring in some patients. Two-component oxaliplatin-containing regimens are the most well studied types of NCT in the treatment of patients with non-metastatic RC. In this connection, despite the differences in the treatment regimens and the number of cycles, a good tolerability of the method as well as no effect on the frequency of postoperative complications and in general a satisfactory results comparable to the effects of CRT were observed. The use of NCT in combination with targeted treatment modalities as well as three-component chemotherapy regimens are promising and encouraging treatment options for patients with RC with adverse prognostic factors.
作者简介
Aleksey Nevolskikh
Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre; Obninsk Institute for Nuclear Power Engineering
Email: nevol@mrrc.obninsk.ru
ORCID iD: 0000-0001-5961-2958
SPIN 代码: 3787-6139
D. Sci. (Med.)
俄罗斯联邦, Obninsk; ObninskVioletta Avdeenko
Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre; Obninsk Institute for Nuclear Power Engineering
编辑信件的主要联系方式.
Email: avdeenko.vita@yandex.ru
ORCID iD: 0000-0002-2678-016X
Student
俄罗斯联邦, Obninsk; ObninskAnna Belokhvostova
Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre
Email: avdeenko.vita@yandex.ru
ORCID iD: 0000-0002-4709-1726
Cand. Sci. (Med.)
俄罗斯联邦, ObninskYuliya Mikhaleva
Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre
Email: avdeenko.vita@yandex.ru
ORCID iD: 0000-0002-9449-2135
Oncologist
俄罗斯联邦, ObninskTaras Pochuev
Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre
Email: avdeenko.vita@yandex.ru
ORCID iD: 0000-0002-9243-6519
SPIN 代码: 1858-0968
Cand. Sci. (Med.)
俄罗斯联邦, ObninskRuslan Zibirov
Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre; Obninsk Institute for Nuclear Power Engineering
Email: avdeenko.vita@yandex.ru
ORCID iD: 0000-0001-5252-0436
SPIN 代码: 6704-9766
Pathologist
俄罗斯联邦, Obninsk; ObninskSergei Ivanov
Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre; Obninsk Institute for Nuclear Power Engineering; People’s Friendship University of Russia (RUDN University)
Email: avdeenko.vita@yandex.ru
ORCID iD: 0000-0001-7689-6032
SPIN 代码: 4264-5167
D. Sci. (Med.), Prof. RAS
俄罗斯联邦, Obninsk; Obninsk; MoscowAndrey Kaprin
National Medical Research Radiological Centre; People’s Friendship University of Russia (RUDN University)
Email: avdeenko.vita@yandex.ru
ORCID iD: 0000-0001-8784-8415
D. Sci. (Med.), Prof., Acad. RAS
俄罗斯联邦, Obninsk; Moscow参考
- Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020; c. 9-10 [Kaprin AD, Starinskii VV, Shakhzadova AO. Zlokachestvennye novoobrazovaniia v Rossii v 2019 godu (zabolevaemost' i smertnost'). Moscow: MNIOI im. PA Gertsena – filial FGBU "NMITs radiologii" Minzdrava Rossii, 2020; p. 9-10 (in Russian)].
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Рак прямой кишки. Рубрикатор клинических рекомендаций. Режим доступа: https://cr.minzdrav.gov.ru/schema/554_2. Ссылка активна на 01.07.2021 [Ministry of Health of the Russian Federation. Clinical guidelines. Rectal cancer. Rubricator of clinical recommendations. Available at: https://cr.minzdrav.gov.ru/schema/554_2. Accessed: 01.07.2021 (in Russian)].
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (version 1.2021). Available at: http://www.nccn.org. Accessed: 02.02.2021.
- Бердов Б.А., Ерыгин Д.В., Невольских А.А., и др. Междисциплинарный подход в лечении рака прямой кишки. Поволжский онкологический вестник. 2015:4:21-8 [Berdov BA, Erygin DV, Nevolskih AA, et al. Interdisciplinary approach in the treatment of cancer of the rectum. Povolzhskiy onkologicheskiy vestnik. 2015:4:21-8 (in Russian)].
- Lutz M, Zalcbergb J, Glynne-Jones R, et al. Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus reconmmendations on controversial issues in the primary treatment of rectal cancer. Eur J Cancer. 2016;63:11-24. doi: 10.1016/j.ejca.2016.04.010
- Bahadoer R, Djkstra A, Ettent B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase3 trial. Lancet Oncol. 2021;22:29-42. doi: 10.1016/S1470-2045(20)30555-6
- Okuyama T, Sameshima S, Takeshita E, et al. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study. World J Surg Oncol. 2018;16:105. doi: 10.1186/s12957-018-1403-9
- Rouanet F, Rullier E, Lelong L, et al. Tailored treatment strategy for locally advanced rectal carcinoma based on the tumor response to induction chemotherapy: preliminary results of the French phase II multicenter GRECCAR4 trial. Dis Colon Rectum. 2017;60(7):653-63. doi: 10.1097/DCR.0000000000000849
- Feng S, Yan P, Zhang Q, et al. Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery for patients with locally advanced rectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2020;35:1355-69. doi: 10.1007/s00384-020-03621-y
- Bujko K, Wyrwicz L, Rutkowski A, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27:834-42. doi: 10.1093/annonc/mdw062
- Ludmir E, Palta M, Willett Ch, et al. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer. 2017;123:1497-506. doi: 10.1002/cncr.30600
- Kasi A, Abbasi S, Handa S, et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer a systematic review and meta-analysis. JAMA Netw Open. 2020;3(12):e2030097. doi: 10.1001/jamanetworkopen.2020.30097
- Ueki T, Manabe T, Inoue S, et al. A Feasibility study of neoadjuvant XELOX without radiotherapy for locally advanced lower rectal cancer. Anticancer Res. 2016;36:741-8.
- Koike J, Funahashil K, Yoshimatsu K, et al. Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage WI rectal cancer: the FACT trial. Cancer Chemother. Pharmacol. 2017;79:519-25. doi: 10.1007/s00280-017-3243-7
- Oshiro T, Uehara K, Aiba T, et al. Impact of RAS/BRAF mutation status in locally advanced rectal cancer treated with preoperative chemotherapy. Int J Clin Oncol. 2018;23:681-8. doi: 10.1007/s10147-018-1253-z
- Ichikawa N, Homma S, Funakoshi T, et al. Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study 2019 – R-NAC-01 trial. Surgery Today. 2019;49(8):712-20. doi: 10.1007/s00595-019-01788-8
- Quezada-Diaz F, Jimenez-Rodriguez R, Pappou E, et al. Effect of neoadjuvant system chemotherapy with or without chemoradiation on bowel function in rectal cancer patients treated with total mesorectal excision. J Gastr Surg. 2019;23:800-7. doi: 10.1007/s11605-018-4003-7
- Manatakis DK, Gouvas N, Souglakos J, et al. Neo-adjuvant chemotherapy alone for the locally advanced rectal cancer: a systematic review. Int J Clin Oncol. 2020;25:1570-80. doi: 10.1007/s10147-020-01738-2
- Bhudia J, Glynne-Jones R, Smith T, et al. Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer. Clin Colon Rectal Surg. 2020;33(5):287-97. doi: 10.1055/s-0040-1713746
- Кочкина С.О., Гордеев С.С., Федянин М.Ю. Результаты комбинированного лечения с применением неоадъювантной химиотерапии без лучевой терапии и короткого курса лучевой терапии у больных раком прямой кишки промежуточного риска. Клиническая и экспериментальная хирургия. 2021;9(1):29-36 [Kochkina SO, Gordeev SS, Fedyanin Myu, et al. Results of combined treatment with neoadjuvant chemotherapy without radiation therapy and a short course of radiation therapy in patients with intermediate-risk rectal cancer. Klinicheskaia i eksperimental'naia khirurgiia. 2021;9(1):29-36 (in Russian)].
- Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;4:22-40. doi: 10.1093/annonc/mdt240
- Taylor F, Quirke Ph, Moran B, et al. Preoperative High-resolution Magnetic Resonance Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone. Ann Surg. 2011;253:711-9. doi: 10.1097/SLA.0b013e31820b8d52
- Nagtegaal I, Quirke P. What Is the Role for the Circumferential Margin in the Modern Treatment of Rectal Cancer. J Clin Oncol. 2008;26:303-12. doi: 10.1200/JCO.2007.12.7027
- Koizumi M, Yamada T, Shinji S, et al. Feasibiliti of neoadjuvant FOLFOX therapy without radiotherapy for baseline resectable rectal cancer. In vivo. 2018;32:937-43. doi: 10.21873/invivo.11332
- Cienfuegos JA, Rodriguez J, Baixauli J, et al. Neoadjuvant chemotherapy without radiotherapy for patients with locally advanced rectal cancer. Rev Esp Enferm Dig. 2020;112(1):16-22. doi: 10.17235/reed.2019.6454/2019
- Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2019;25(1):1-42. doi: 10.1007/s10147-019-01485-z
- ALGizawy SM, Essa HH, Ahmed BM. Chemotherapy alone for patients with stage II/III rectal cancer undergoing radical surgery. Oncologist. 2015;20:752-7. doi: 10.1634/theoncologist.2015-0038
- Гордеев С.С., Расулов А.О., Мамедли З.З. Неоадьювантная химиотерапия колоректального рака – время изучать новую стратегию лечения? Вопросы онкологии. 2014;60(1):18-24 [Gordeev SS, Rasulov AO, Mamedly ZZ, et al. Neoadjuvant chemotherapy for colorectal cancer – the time to learn a new treatment strategy? Voprosy onkologii. 2014;60(1):18-24 (in Russian)]. doi: 10.37469/0507-3758-2014-60-1-18-24
- US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. Rockville: National Cancer Institute; 2017. Available at: https://ctep.cancer.gov/ Accessed: 15.05.2022.
- Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol. 2015;26:1722-8. doi: 10.1093/annonc/mdv223
- Miwa K, Oki E, Enomoto M, et al. Randomized phase ll study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301). BMC Cancer. 2021;21(1):23. doi: 10.1186/s12885-020-07766-5
- Shiraishi T, Sasaki T, Ikeda K, et al. Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer. BMC Cancer. 2019;19:1222. doi: 10.1186/s12885-019-6424-4
- Nishimura J, Hasegawa J, Kato T, et al. Phase II trial of capecitabine plus oxaliplatin (CAPOX) as preoperative therapy for locally advanced rectal cancer. Cancer Chemotherapy and Pharmacology. 2018;82:707-16. doi: 10.1007/s00280-018-3663-z
- Deng Y, Chi P, Lan P, et al. Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. J Clin Oncol. 2019;37:3223-33. doi: 10.1200/JCO.18.02309
- Cercek A, Campbell S, Paul S, et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncology. 2018;4(6):e180071. doi: 10.1001/jamaoncol.2018.0071
- Yamamoto T, Kawada K, Hida K, et al. Optimal treatment strategy for rectal cancer based on the risk factor for recurrence patterns. Int J Clin Oncol. 2019;24:677-85. doi: 10.1007/s10147-019-01400-6
- Lin H, Wang L, Zhong X, et al. Meta-analysis of neoadjuvant chemoradiotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer. World J Surg Oncol. 2021;19:141. doi: 10.1186/s12957-021-02251-0
- Ishii Y, Hasegawa H, Endo T, et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. EJSO. 2010;36:1061-5. doi: 10.1016/j.ejso.2010.05.017
- Невольских А.А., Авдеенко В.А., Белохвостова А.С., и др. Неоадъювантная химиотерапия как альтернатива лучевой терапии в лечении больных прогностически неблагоприятным раком прямой кишки. Колопроктология. 2022;21(2):91-104 [Nevolskikh AA, Avdeenko VA, Belohvostova AS, et al. Neoadjuvant chemotherapy without radiation therapy for rectal cancer with negative prognosis. Koloproktologia. 2022;21(2):91-104 (in Russian)]. doi: 10.33878/2073-7556-2022-21-2-91-104
- Zhang J, Huang M, Yue Cai Y, et al. Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer. Clin Colorectal Cancer. 2019;18(4):238-44. doi: 10.1016/j.clcc.2019.07.001
- Koadama H, Terazawa T, Ishizuka Y, et al. Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer. In vivo. 2021;35:977-85. doi: 10.21873/invivo.12340
- Ding M, Zhang J, Hu H, et al. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis. Clin Colorectal Cancer. 2022;1:12-20. doi: 10.1016/j.clcc.2021.11.009
- Rouanet Ph, Rullier E, Lelong B, et al. Tailored Treatment Strategy for Locally Advanced Rectal Carcinoma Based on the Tumor Response to Induction Chemotherapy: Preliminary Results of the French Phase II Multicenter GRECCAR4 Trial. Dis Colon Rectum. 2017;7:653-63. doi: 10.1097/DCR.0000000000000849
- Brouquet A, Bachet J, Huguet F, et al. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial). BMC Cancer. 2020;1:485-9. doi: 10.1186/s12885-020-06968-1
- Suarez J, Amat I, Vera R, et al. Pathologic Response of Primary Rectal Cancer to Oxaliplatin-Based Chemotherapy. Clin Colon Rectal Surg. 2011;24:119-24. doi: 10.1055/s-0031-1278409
- Suenaga M, Fujimoto Y, Matsusaka S, et al. Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). Onco Targets Ther. 2015;8:1111-8. doi: 10.2147/OTT.S83952
- Song J, Wang Y, Yu H, et al. Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety. Comput Math Methods Med. 2021;2021:4227650. doi: 10.1155/2021/4227650
- Hasegawa S, Goto S, Matsumoto T, et al. A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer. Ann Surg Oncol. 2017;24:3587-95. doi: 10.1245/s10434-017-5967-3
- Tokuhara K, Matsui Y, Ueyama Y, et al. Feasibility and Efficacy of Neoadjuvant Chemotherapy without Radiotherapy for Locally Advanced Rectal Cancer. J Anus Rectum Colon. 2022;6:24-31.
- Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial. J Clin Oncol. 2014;6:513-8. doi: 10.1200/JCO.2013.51.7904
- Nishimura J, Hasegawa J, Noura S, et al. Adjuvant Chemotherapy after Neoadjuvant Chemotherapy and Long-term Outcomes of CAPOX Plus Bevacizumab Followed by TME for High-risk Localized Rectal Cancer. J Anus Rectum Colon. 2020;4:108-13. doi: 10.23922/jarc.2019-042
- Gollub M, Gultekin D, Akin O, et al. Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. Eur Radiol. 2012;22:821-31. doi: 10.1007/s00330-011-2321-1
- Fernandez-Martos С, Pericay C, Losa F, et al. Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma. The GEMCAD 1402 Randomized Clinical Trial. JAMA Oncol. 2019;5(11):1566-73.
- Nishizawa Y, Saitoa N, Fujiib S, et al. Association between Anal Function and Therapeutic Effect after Preoperative Chemoradiotherapy followed by Intersphincteric Resection. Dig Surg. 2012;29:439-45. doi: 10.1159/000345586
- Sakuyama N, Kojima M, Kawano S, et al. Histological differences between preoperative chemoradiotherapy and chemotherapy for rectal cancer: a clinicopathological study. Pathol Int. 2016;66:273-80. doi: 10.1111/pin.12409
- Hasegawa J, Nishimura J, Mizushima T, et al. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol. 2014;73:1079-87. doi: 10.1007/s00280-014-2417-9
- Borg C, Andre T, Mantion G, et al. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study. Ann Oncol. 2014;25:2205-10. doi: 10.1093/annonc/mdu377
- Patel UB, Brown G, Machado I, et al. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. Ann Oncol. 2017;28:344-53. doi: 10.1093/annonc/mdw616
- Tomida A, Uehara K, Hiramatsu K, et al. Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial. Int J Clin Oncol. 2019;24:403-10. doi: 10.1007/s10147-018-1372-6
- Bisschop C, Dijk TH, Beukema JC, et al. Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study. Ann Surg Oncol. 2017;24:2632-8. doi: 10.1245/s10434-017-5897-0